Skip to content

Study · Case report or series · n = 1 · 2024

1 result

When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion.

Rovaris S, La Rosa G, Mezzana S, Tonon F, Mori L, Monti E, Mazzeo G, Calzavara-Pinton P, Arisi M

Dermatology reports13 Sept 2023

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 21-year-old man with erythropoietic protoporphyria and a chromosome-18 deletion, clinical condition improved after an afamelanotide implant.

    In plain wordsIn one young man with EPP, his condition improved after an afamelanotide implant.

    Outcome
    Not applicableClinical condition after afamelanotide implant
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · implantAs given in this study (human).

    Source sentences

    Summary
    The patient's clinical condition improved following the June 2022 afamelanotide implant procedure.
    1 context sentence
    Summary · context
    In this case study, we describe a 21-year-old man with erythropoietic protoporphyria who sought medical attention in April 2022 for diffuse edema and erythema of the hands.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.